All-oral combination of lapatinib and capecitabine in patients with brain metastases from HER2-positive breast cancer - A phase II study

Journal of the Egyptian National Cancer Institute

Volumn 26, Issue 4, 2014, Pages 187-194

  Shawky, Hanan ^a   Tawfik, Hesham ^a  

^a TANTA UNIVERSITY HOSPITAL   (Egypt)

Author keywords

Brain metastases; Capecitabine; HER2 positive breast cancer; Lapatinib

Indexed keywords

BILIRUBIN; CAPECITABINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; LAPATINIB; ANTINEOPLASTIC AGENT; ERBB2 PROTEIN, HUMAN; QUINAZOLINE DERIVATIVE;

ADULT; AGED; ARTICLE; BRAIN METASTASIS; BREAST CANCER; CANCER RADIOTHERAPY; CLINICAL ARTICLE; DIARRHEA; DRUG EFFICACY; DRUG TOLERABILITY; HAND FOOT SYNDROME; HUMAN; MORNING DOSAGE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PROGRESSION FREE SURVIVAL; RASH; SIDE EFFECT; TREATMENT RESPONSE; WHOLE BRAIN RADIOTHERAPY; BRAIN NEOPLASMS; BREAST TUMOR; CLINICAL TRIAL; DISEASE COURSE; DISEASE FREE SURVIVAL; FEMALE; KAPLAN MEIER METHOD; METABOLISM; METASTASIS; MIDDLE AGED; PATHOLOGY; PROGNOSIS; PROSPECTIVE STUDY; SECONDARY; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRAIN NEOPLASMS; BREAST NEOPLASMS; CAPECITABINE; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MIDDLE AGED; NEOPLASM METASTASIS; PROGNOSIS; PROSPECTIVE STUDIES; QUINAZOLINES; RECEPTOR, ERBB-2; TREATMENT OUTCOME;

EID: 84922332382     PISSN: 11100362     EISSN: 16879996     Source Type: Journal    
DOI: 10.1016/j.jnci.2014.08.001     Document Type: Article

References (26)

1. Cetin B., Benekli M., Oksuzoglu B., Koral L., Ulas A., Dane F., et al. Lapatinib plus Capecitabine for Brain Metastases in Patients with Human Epidermal Growth Factor Receptor 2-Positive Advanced Breast Cancer: A Review of the Anatolian Society of Medical Oncology (ASMO) Experience. Onkologie 2012, 35:5-740.
2. Capri G., Chang J., Chen S.-C., Conte P., Cwiertka K., Jerusalem G., et al. An open-label expanded access study of lapatinib and capecitabine in patients with HER2-overexpressing locally advanced or metastatic breast cancer. Ann Oncol 2010, 21(3):80-474.
3. Kamar F.G., Posner J.B. Brain metastases. Semin Neurol 2010, 30(3):217-235.
4. Kennecke H., Yerushalmi R., Woods R., Cheang M.C.U., Voduc D., Speers C.H., et al. Metastatic behavior of breast cancer subtypes. J Clin Oncol 2010, 28:7-3271.
5. Lin N., Bellon J., Winer E. CNS metastases in breast cancer. J Clin Oncol 2004, 22:17-3608.
6. Weil R., Palmieri D., Bronder J., Stark A., Steeg P. Breast cancer metastasis to the central nervous system. Am J Pathol 2005, 167(4):20-913.
7. Lin N.U., Dieras V., Paul D., Lossignol D., Christodoulou C., Stemmler H.-J., et al. Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer. Clin Cancer Res 2009, 15(4):9-1452.
8. Piccart-Gebhart M.J., Procter M., Leyland-Jones B., Goldhirsch A., Untch M., Smith I., et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005, 353:72-1659.
9. Romond E.H., Perez E.A., Bryant J., Suman V.J., Geyer C.E., Davidson N.E., et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005, 353:84-1673.
10. Bendell J.C., Domchek S.M., Burstein H.J., Harris L., Younger J., Kuter I., et al. Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma. Cancer 2003, 97:7-2972.
11. Burstein H.J., Lieberman G., Slamon D.J., Winer E.P., Klein P. Isolated central nervous system metastases in patients with HER2-overexpressing advanced breast cancer treated with first-line trastuzumab-based therapy. Ann Oncol 2005, 16:7-1772.
12. Stemmler H.J., Schmitt M., Willems A., Bernhard H., Harbeck N., Heinemann V. Ratio of trastuzumab levels in serum and cerebrospinal fluid is altered in HER2-positive breast cancer patients with brain metastases and impairment of blood-brain barrier. Anticancer Drugs 2007, 18(1):8-23.
13. Pestalozzi B.C., Brignoli S. Trastuzumab in CSF. J Clin Oncol 2000, 18:51-2349.
14. Polli J., Humphreys J.E., Harmon K.A., Castellino S., O'Mara M.J., Olson K.L., et al. The role of efflux and uptake transporters in [N-{3-chloro-4-[(3-fluorobenzyl) oxy]phenyl}-6-[5-({[2-(methylsulfonyl) ethyl]amino} methyl)-2-furyl]-4-quinazolinamine (GW572016, lapatinib) disposition and drug interactions. Drug Metable Dispos 2008, 36:695-701.
15. Chefrour M., Milano G., Formento P., Giacometti S., Denden A., Renée N., et al. Positive interaction between lapatinib and capecitabine in human breast cancer models: study of molecular determinants. Positive interaction between lapatinib and capecitabine in human breast cancer models: study of molecular determinants. Fundam Clin Pharmacol 2012, 26:7-530.
16. Therasse P., Arbuck S.G., Eisenhauer E.A., Wanders J., Kaplan R.S., Rubinstein L., et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000, 92(3):16-205.
17. National Cancer Institute, US. NCI common terminology criteria for adverse events v3.0 (CTCAE v3.0) [online], [accessed April 7, 2014]. http://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/ctcaev3.pdf.
18. Kaplan E.L., Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958, 53:81-457.
19. Metro G., Foglietta J., Russillo M., Stocchi L., Vidiri A., Giannarelli D., et al. Clinical outcome of patients with brain metastases from HER2-positive breast cancer treated with lapatinib and capecitabine. Ann Oncol 2011, 22:30-625.
20. Bachelot T., Romieu G., Campone M., Diéras V., Cropet C., Dalenc F., et al. Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study. Lancet Oncol 2013, 14:7-64.
21. Lin N.U., Eierman W., Greil R., Campone M., Kaufman B., Steplewski K., et al. Randomized phase II study of lapatinib plus capecitabine or lapatinib plus topotecan for patients with HER2-positive breast cancer brain metastases. J Neurooncol 2011, 105(3):20-613.
22. Sutherland S., Ashley S., Miles D., Chan S., Wardley A., Davidson N., et al. Treatment of HER2-positive metastatic breast cancer with lapatinib and capecitabine in the lapatinib expanded access programme, including efficacy in brain metastases-the UK experience. Br J Cancer 2010, 102:995-1002.
23. Boccardo F, Kaufman B, Baselga J, Dieras V, Link J, Casey MA, et al. Evaluation of lapatinib (Lap) plus capecitabine (Cap) in patients with brain metastases (BM) from HER2+ breast cancer (BC) enrolled in the Lapatinib Expanded Access Program (LEAP) and French Authorisation Temporaire d'Utilisation (ATU). J Clin Oncol 2008, 26. (abstr 1094).
24. Bachelot TD, Romieu G, Campone M, Dieras V, Cropet C, Roche HH, et al. LANDSCAPE: an FNCLCC phase II study with lapatinib (L) and capecitabine (C) in patients with brain metastases (BM) breast cancer (MBC) before whole-brain radiotherapy (WBR). J Clin Oncol 2011, 29. (suppl; abstr 509).
25. Kaplan MA, Isikdogan A, Koca D, Kucukoner M, Gumusay O, Yildiz R, et al. Clinical outcomes in patients who received lapatinib plus capecitabine combination therapy for HER2-positive breast cancer with brain metastasis and a comparison of survival with those who received trastuzumab-based therapy: a study by the Anatolian Society of Medical Oncology. Breast Cancer. ISSN: 1340-6868 (Print) 1880-4233 (Online). DOI 10.1007/s12282-013-0441-y.
26. Park Y.H., Park M.J., Ji S.H., Yi S.Y., Lim D.H., Nam D.H., et al. Trastuzumab treatment improves brain metastasis outcomes through control and durable prolongation of systemic extracranial disease in HER2-overexpressing breast cancer patients. Br J Cancer 2009, 100(6):894-900.